148 related articles for article (PubMed ID: 31292669)
21. Bufalin induces G0/G1 phase arrest through inhibiting the levels of cyclin D, cyclin E, CDK2 and CDK4, and triggers apoptosis via mitochondrial signaling pathway in T24 human bladder cancer cells.
Huang WW; Yang JS; Pai SJ; Wu PP; Chang SJ; Chueh FS; Fan MJ; Chiou SM; Kuo HM; Yeh CC; Chen PY; Tsuzuki M; Chung JG
Mutat Res; 2012 Apr; 732(1-2):26-33. PubMed ID: 22285700
[TBL] [Abstract][Full Text] [Related]
22. PIM1: a promising target in patients with triple-negative breast cancer.
Zhao W; Qiu R; Li P; Yang J
Med Oncol; 2017 Aug; 34(8):142. PubMed ID: 28721678
[TBL] [Abstract][Full Text] [Related]
23. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.
Ai Z; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Apr; 373(1):36-44. PubMed ID: 26801746
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of PIM1 blocks the autophagic flux to sensitize glioblastoma cells to ABT-737-induced apoptosis.
Remy J; Linder B; Weirauch U; Konovalova J; Marschalek R; Aigner A; Kögel D
Biochim Biophys Acta Mol Cell Res; 2019 Feb; 1866(2):175-189. PubMed ID: 30389373
[TBL] [Abstract][Full Text] [Related]
25. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
Ramadoss S; Sen S; Ramachandran I; Roy S; Chaudhuri G; Farias-Eisner R
Oncogene; 2017 Mar; 36(11):1537-1545. PubMed ID: 27694900
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of glycolysis enhances cisplatin-induced apoptosis in ovarian cancer cells.
Loar P; Wahl H; Kshirsagar M; Gossner G; Griffith K; Liu JR
Am J Obstet Gynecol; 2010 Apr; 202(4):371.e1-8. PubMed ID: 20138251
[TBL] [Abstract][Full Text] [Related]
27. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
[TBL] [Abstract][Full Text] [Related]
28. Pim1 promotes cell proliferation and regulates glycolysis via interaction with MYC in ovarian cancer.
Wu Y; Deng Y; Zhu J; Duan Y; Weng W; Wu X
Onco Targets Ther; 2018; 11():6647-6656. PubMed ID: 30349298
[TBL] [Abstract][Full Text] [Related]
29. Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail‑glycolysis pathways.
Jia L; Zhou J; Zhao H; Jin H; Lv M; Zhao N; Zheng Z; Lu Y; Ming Y; Yu Y
Oncol Rep; 2017 Oct; 38(4):2464-2470. PubMed ID: 28791374
[TBL] [Abstract][Full Text] [Related]
30. Anticancer effects of (-)-epigallocatechin-3-gallate on ovarian carcinoma cell lines.
Huh SW; Bae SM; Kim YW; Lee JM; Namkoong SE; Lee IP; Kim SH; Kim CK; Ahn WS
Gynecol Oncol; 2004 Sep; 94(3):760-8. PubMed ID: 15350370
[TBL] [Abstract][Full Text] [Related]
31. Licochalcone A suppresses hexokinase 2-mediated tumor glycolysis in gastric cancer via downregulation of the Akt signaling pathway.
Wu J; Zhang X; Wang Y; Sun Q; Chen M; Liu S; Zou X
Oncol Rep; 2018 Mar; 39(3):1181-1190. PubMed ID: 29286170
[TBL] [Abstract][Full Text] [Related]
32. Kinase PIM1 promotes prostate cancer cell growth via c-Myc-RPS7-driven ribosomal stress.
Zhang C; Qie Y; Yang T; Wang L; Du E; Liu Y; Xu Y; Qiao B; Zhang Z
Carcinogenesis; 2019 Mar; 40(1):52-60. PubMed ID: 30247545
[TBL] [Abstract][Full Text] [Related]
33. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
[TBL] [Abstract][Full Text] [Related]
34. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
35. Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling.
Montero JC; García-Alonso S; Ocaña A; Pandiella A
Oncotarget; 2015 Oct; 6(30):30057-71. PubMed ID: 26336133
[TBL] [Abstract][Full Text] [Related]
36. Selective anti-tumor activity of wogonin targeting the Warburg effect through stablizing p53.
Zhao Y; Zhang L; Wu Y; Dai Q; Zhou Y; Li Z; Yang L; Guo Q; Lu N
Pharmacol Res; 2018 Sep; 135():49-59. PubMed ID: 30031170
[TBL] [Abstract][Full Text] [Related]
37. Resibufogenin Induces G1-Phase Arrest through the Proteasomal Degradation of Cyclin D1 in Human Malignant Tumor Cells.
Ichikawa M; Sowa Y; Iizumi Y; Aono Y; Sakai T
PLoS One; 2015; 10(6):e0129851. PubMed ID: 26121043
[TBL] [Abstract][Full Text] [Related]
38. PIM1 kinase promotes cell proliferation, metastasis and tumor growth of lung adenocarcinoma by potentiating the c-MET signaling pathway.
Cao L; Wang F; Li S; Wang X; Huang D; Jiang R
Cancer Lett; 2019 Mar; 444():116-126. PubMed ID: 30583073
[TBL] [Abstract][Full Text] [Related]
39. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
40. LncRNA HOXA11-AS Promotes Proliferation and Cisplatin Resistance of Oral Squamous Cell Carcinoma by Suppression of miR-214-3p Expression.
Wang X; Li H; Shi J
Biomed Res Int; 2019; 2019():8645153. PubMed ID: 31275988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
